Thalidomide in combination with dexamethasone-induced rhabdomyolysis in a patient with refractory myeloma
Boga, C.; Ozdogu, H.; Yeral, M.; Kizilkilic, E.; Tamer, L.
Journal of Supportive Oncology 5(6): 256
2007
ISSN/ISBN: 1544-6794 PMID: 17624049 Document Number: 607700
Document emailed within 1 workday
Related Documents
Dingli, D.; Rajkumar, S.Vincent.; Nowakowski, G.S.; Gertz, M.A.; Dispenzieri, A.; Lacy, M.Q.; Hayman, S.; Fonseca, R.; Lust, J.A.; Kyle, R.A.; Greipp, P.R.; Witzig, T.E. 2005: Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial Haematologica 90(12): 1650-1654Wölfler, A.; Bauer, F.; Zollner, G.; Weber, K.; Sill, H.; Linkesch, W. 2003: Fatal sepsis after thalidomide/dexamethasone treatment in two patients with multiple myeloma Haematologica 88(4): Elt12
Dimopoulos, M.A.; Anagnostopoulos, A.; Terpos, E.; Repoussis, P.; Zomas, A.; Katodritou, E.; Kyrtsonis, M.Christine.; Delibasi, S.; Vassou, A.; Pouli, A.; Zervas, K.; Anagnostopoulos, N.; Maniatis, A. 2006: Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma Haematologica 91(2): 252-254
Dadacaridou, M.; Papanicolaou, X.; Maltesas, D.; Megalakaki, C.; Patos, P.; Panteli, K.; Repousis, P.; Mitsouli-Mentzikof, C. 2007: Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients Journal of BUON: Official Journal of the Balkan Union of Oncology 12(1): 41-44
Pitini, V.; Arrigo, C.; Aloi, G.; Azzarello, D.; La Gattuta, G. 2002: Diabetic foot disease in a patient with multiple myeloma receiving thalidomide Haematologica 87(2): Elt07
Yuan, Z.-g.; Hou, J.; Wang, D.-x.; Fu, W.-j.; Chen, Y.-b.; Xi, H. 2008: Bortezomib-based combination therapy for relapsed or refractory multiple myeloma Zhonghua Nei Ke Za Zhi 47(2): 102-106
Adam, Z.; Elbl, L.; Vorlícek, J.; Hájek, R.; Tomíska, M.; Hejlová, N.; Králová, E.; Novotná, H. 1994: Lower cardiotoxicity of adriamycin during continuous administration in patients with refractory multiple myeloma treated with cyclophosphamide, vincristine, adriamycin and dexamethasone (C-VAD) Vnitrni Lekarstvi 40(8): 506-512
Li, X.; Sun, W.; Jin, F.; Chen, S.; Zhong, Y.; Hu, Y.; Zhang, J.; An, N.; Shen, M.; Huang, Z. 2014: Clinical observation of DECP combination chemotherapy for relapsing and refractory multiple myeloma patients with extramedullary plasmacytomas Zhonghua Yi Xue Za Zhi 94(16): 1258-1260
Liu, P.; Oken, M.; Van Ness, B. 1999: Interferon-alpha protects myeloma cell lines from dexamethasone-induced apoptosis Leukemia 13(3): 473-480
Prakash, O.; Medhi, B.; Saikia, U.N.; Pandhi, P. 2011: Effect of combination of thalidomide and sulfasalazine in experimentally induced inflammatory bowel disease in rats Indian Journal of Experimental Biology 49(9): 672-678
Sirvent, A.E.; Cabezuelo, J.B.; Enríquez, R.; Amorós, F.; González, C.; Reyes, A. 2001: Rhabdomyolysis and anuric kidney failure induced by the treatment with a gemfibrozil-cerivastatin combination Nefrologia: Publicacion Oficial de la Sociedad Espanola Nefrologia 21(5): 497-500
Koutsilieris, M.; Reyes-Moreno, C.; Sourla, A.; Dimitriadou, V.; Choki, I. 1997: Growth factors mediate glucocorticoid receptor function and dexamethasone-induced regression of osteoblastic lesions in hormone refractory prostate cancer Anticancer Research 17(3a): 1461-1465
Romanenko, N.A.; Bessmel'tsev, S.S.; Udal'eva, V.I.; Zenina, M.N.; Martynkevich, I.S.; Rugal', V.I.; Abdulkadyrov, K.M. 2013: The combination of chronic myeloid leukemia and multiple myeloma in one patient Voprosy Onkologii 59(2): 103-110
Maddali, M.M.; Mathew, J.; Fahr, J.; Zarroug, A.W. 2003: Postoperative nausea and vomiting in diagnostic gynaecological laparoscopic procedures: comparison of the efficacy of the combination of dexamethasone and metoclopramide with that of dexamethasone and ondansetron Journal of Postgraduate Medicine 49(4): 302-306
Hansen, M.; Hansen, P.B. 2006: Refractory anaemia successfully treated with thalidomide Ugeskrift for Laeger 168(6): 591-592
Keesal, N.; Wasserman, M.J.; Bookman, A.; Lapp, V.; Weber, D.A.; Keystone, E.C. 1999: Thalidomide in the treatment of refractory rheumatoid arthritis Journal of Rheumatology 26(11): 2344-2347
Garcia-del-Muro, X.; Vadell, C.; Pérez Manga, G.; Bover, I.; Rifá, J.; Beltrán, M.; Barros, M.M.; Germá, J.R.; Fabregat, X.; Moreno, V.; Salvador, A.; Viladiu, P. 1998: Randomised double-blind study comparing tropisetron alone and in combination with dexamethasone in the prevention of acute and delayed cisplatin-induced emesis European Journal of Cancer 34(1): 193-195
Chou, T. 2007: Development of thalidomide analogs for the treatment of multiple myeloma (MM) Nihon Rinsho. Japanese Journal of Clinical Medicine 65(12): 2302-2308
Katayama, Y.; Kojima, K.; Omoto, E.; Harada, M. 1996: Androgen therapy in combination with granulocyte colony-stimulating factor and erythropoietin in a patient with refractory anemia International Journal of Hematology 65(1): 89-92
Jurczyszyn, A.; Wolska-Smoleń, T.; Skotnicki, A.B. 2003: Multiple myeloma: the role of angiogenesis and therapeutic application of thalidomide Przeglad Lekarski 60(8): 542-547